Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Barbara Jezeršek Novaković, Lučka Boltežar & Aleksander Novaković. (2021) Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma. Therapeutics and Clinical Risk Management 17, pages 183-192.
Read now
Read now
Gilles A. Salles, Ruth Pettengell, Raul Cordoba, Monika Długosz-Danecka, Wojciech Jurczak & Hervé Tilly. (2019) Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review. Leukemia & Lymphoma 60:7, pages 1610-1625.
Read now
Read now
Kai Hübel. (2018) An evaluation of pixantrone for the treatment of non-Hodgkin’s lymphoma. Expert Opinion on Pharmacotherapy 19:16, pages 1829-1834.
Read now
Read now
Giorgio Minotti, Haiyong Han, Valérie Cattan, Anton Egorov & Francesco Bertoni. (2018) Pixantrone: novel mode of action and clinical readouts. Expert Review of Hematology 11:7, pages 587-596.
Read now
Read now
Ruth Pettengell & Jasvinder Kaur. (2015) Pixantrone dimaleate for treating non-Hodgkin’s lymphoma. Expert Opinion on Orphan Drugs 3:6, pages 747-757.
Read now
Read now
Eileen Mary Boyle & Franck Morschhauser. (2015) Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma. Expert Opinion on Drug Safety 14:4, pages 601-607.
Read now
Read now
Pier Luigi Zinzani, Massimo Federico, Stefano Oliva, Antonello Pinto, Luigi Rigacci, Giorgina Specchia, Alessandra Tucci & Umberto Vitolo. (2015) The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma. Leukemia & Lymphoma 56:1, pages 12-25.
Read now
Read now
Stefano Volpetti, Francesco Zaja & Renato Fanin. (2014) Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. OncoTargets and Therapy 7, pages 865-872.
Read now
Read now
Dionysios Papadatos-Pastos & Ruth Pettengell. (2013) Pixantrone: merging safety with efficacy. Expert Review of Hematology 6:1, pages 25-33.
Read now
Read now
Mariam Jamal-Hanjani & Ruth Pettengell. (2011) Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma. Expert Opinion on Drug Metabolism & Toxicology 7:11, pages 1441-1448.
Read now
Read now
Articles from other publishers (11)
Cristina Barrenetxea Lekue, Silvina Grasso Cicala, Sirpa Leppä, Thomas Stauffer Larsen, Susana Herráez Rodríguez, Clara Alonso Caballero, Judit M. Jørgensen, Helle Toldbod, Irene Leal Martínez & Francesco D’Amore. (2019) Pixantrone beyond monotherapy: a review. Annals of Hematology 98:9, pages 2025-2033.
Crossref
Crossref
Chiara Tarantelli, Eugenio Gaudio, Luciano Cascione, Anastasios Stathis, Emanuele Zucca & Francesco Bertoni. (2018)
In vitro
demonstration of synergism with pixantrone combined with targeted agents in lymphomas
. British Journal of Haematology 186:1, pages 149-152.
Crossref
Crossref
Wojciech Jurczak, Monika Długosz-Danecka & Fernando Rivas Navarro. (2019) The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions. Future Oncology 15:3, pages 305-317.
Crossref
Crossref
Benjamin Heyman, David Rizzieri, David J. Adams, Carlos De Castro, Louis Diehl, Zhiguo Li, Joseph Moore & Anne Beaven. (2018) Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Clinical Lymphoma Myeloma and Leukemia 18:10, pages 679-686.
Crossref
Crossref
Pier Luigi Zinzani, Paolo Corradini, Maurizio Martelli, Giorgio Minotti, Stefano Oliva, Michele Spina, Giovanni Barosi & Sante Tura. (2016) Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper. European Journal of Haematology 97:6, pages 554-561.
Crossref
Crossref
Boyd M. Koffman, Miles Hacker, William T. Gunning & Anthony Quinn. (2016) Something Old, New, Borrowed, Blue. Clinical Neuropharmacology 39:2, pages 102-111.
Crossref
Crossref
R. Herbrecht, P. Cernohous, A. Engert, S. Le Gouill, D. Macdonald, C. Machida, H. Myint, A. Saleh, J. Singer, M. Wilhelm & R. van der Jagt. (2013) Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma. Annals of Oncology 24:10, pages 2618-2623.
Crossref
Crossref
Andrew Furness & Ruth Pettengell. (2013) Pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma. International Journal of Hematologic Oncology 2:4, pages 315-323.
Crossref
Crossref
W.A. Denny. 2013. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering.
Anne W Beaven & David Rizzieri. (2012) Clinical evidence for the role of pixantrone in the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma. Clinical Investigation 2:1, pages 49-58.
Crossref
Crossref
Jirouta Kitagaki & Yili Yang. (2011) DNA intercalator korkormicin A preferentially kills tumor cells expressing wild type p53. Biochemical and Biophysical Research Communications 414:1, pages 186-191.
Crossref
Crossref